Othera Pharmaceuticals announced positive interim data results from its Phase 2 OMEGA (OT-551 Multi-center Evaluation of Geographic Atrophy) trial of OT-551 in treating geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). This 2-year, randomized, double-masked, dose-ranging, multi-center study has enrolled 137 patients at 20 retinal disease treatment centers across the U.S. The 12-month findings from this trial suggest an emerging trend for reducing moderate vision loss (i.e., 15 letters or more on the ETDRS chart) in patients treated with OT-551 compared with placebo. This numeric trend was more pronounced in subgroups based on GA characteristics or level of visual acuity at baseline.
OT-551 is a topically-dosed, small molecule that acts on oxidative stress and disease-induced inflammation, two factors that have been linked to the progression of GA and the ensuing vision loss in patients. OT-551 is the first eye drop to ever be tested in a clinical trial as a treatment for dry AMD.
For more information call (877) 551-8240 or visit www.othera.com.